A Phase 1 study of a preventive HIV vaccine show that a novel delivery mechanism known as electroporation helped to enhance the immunogenicity of the vaccine tested. Results were presented at the end of October at the AIDS Vaccine Conference in Paris, France. Please see the IAVI and Ichor Medical Systems, Inc. announcement below for more information.

Visit the new AVAC web site: www.avac.org. The site contains AVAC’s comprehensive coverage of the full range of biomedical HIV prevention interventions in an easy-to-use format that is searchable by intervention and by topic like policy, ethics and community involvement in research.

To support the Global HIV Vaccine Enterprise’s efforts to raise the visibility and participation in the HIV vaccine field of Young and Early Career Investigators, the CAVD recognizes the young or early career investigators who have made significant contributions to research conducted within the CAVD. For more information, please click here.

The International AIDS Vaccine Initiative (IAVI) announced today that it has signed a memorandum of understanding with the Ragon Institute to accelerate the development of new and promising AIDS vaccine candidates for testing

MSD Wellcome Trust Hilleman Laboratories is a first of its kind research and development joint venture with a not-for-profit mission focusing on developing affordable vaccines to prevent diseases that commonly affect low-income countries. For more information, please see the press release below.

Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus.